Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 2.02B +166.2% |
| Revenue (ttm) | 217.17M +396.7% |
| Net Income | -243.25M |
| EPS | -2.79 |
| Shares Out | 88.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,061,474 |
| Open | 22.34 |
| Previous Close | 22.71 |
| Day's Range | 22.24 - 23.45 |
| 52-Week Range | 9.16 - 25.59 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+71.05%) |
| Earnings Date | Aug 3, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 71.05% from the latest price.
News
Syndax Pharmaceuticals Transcript: R&D Day 2026
The company is advancing a robust pipeline with late-stage and next-gen assets in leukemia, GVHD, IPF, myelofibrosis, and EGFR-mutant NSCLC. Multiple pivotal trials and IND filings are expected through 2027, supported by strong financials and strategic collaborations.
Syndax Pharmaceuticals Slides: FY 2026
Syndax Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on July 14, 2026.
Syndax Pharmaceuticals Press release: FY 2026
Syndax Pharmaceuticals issued a press release on July 14, 2026, disclosing material business information to investors.
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2...
Syndax price target lowered to $31 from $34 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Syndax (SNDX) to $31 from $34 and keeps a Buy rating on the shares. The firm updated its acute myeloid…
Syndax presents data from SAVE trial at EHA
Syndax (SNDX) announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj, decitabine/cedazuridine, and venetoclax in relapsed or refractory NPM1 mutated, KMT2A-rearranged, or...
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups...
Syndax Pharmaceuticals Transcript: AGM 2026
The meeting covered board introductions, five key proposals, and voting outcomes, with all proposals—including director elections, executive compensation, auditor ratification, and two employee plans—approved by strong majorities. No questions were submitted by stockholders.
Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong R&D and commercialization capabilities have driven rapid product launches and market penetration, especially for Revuforj in AML. Recent clinical data and financial moves support expansion into new indications and geographies, with a robust pipeline and pivotal trials underway.
Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Management highlighted strong commercial momentum for two oncology products, a new $250M convertible debt facility, and robust late-stage and early pipeline progress. Key data readouts for IPF and GVHD are expected in Q4, with ongoing pivotal trials and dominant market share in core indications.
Syndax Pharmaceuticals Proxy statement: Proxy filing
Syndax Pharmaceuticals filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Syndax announces $250M convertible senior note offering due 2031
07:38 EDT Syndax (SNDX) announces $250M convertible senior note offering due 2031
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into...
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90%...
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host...
Syndax Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Strong clinical data for Revuforj and Niktimvo support leadership in menin inhibition and GVHD, with robust sales growth and expanding patient reach. Ongoing pivotal trials, real-world evidence, and new maintenance strategies are expected to drive further adoption and potential guideline inclusion.
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
Syndax Announces Participation in Upcoming Investor Conferences
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Me...
Syndax price target lowered to $37 from $38 at UBS
UBS lowered the firm’s price target on Syndax (SNDX) to $37 from $38 and keeps a Buy rating on the shares.
Syndax reports 12 Revuforj abstracts accepted for EHA
Syndax (SNDX) Pharmaceuticals highlighted the release of 12 Revuforj abstracts on the European Hematology Association website in advance of the EHA 2026 Congress, taking place June 11-14. “The breadth...
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability ...
Syndax price target raised to $46 from $45 at Stifel
Stifel raised the firm’s price target on Syndax (SNDX) to $46 from $45 and keeps a Buy rating on the shares. Despite modest consensus misses on Revuforj and Niktimvo sales…
Syndax price target lowered to $37 from $40 at Jefferies
Jefferies lowered the firm’s price target on Syndax (SNDX) to $37 from $40 and keeps a Buy rating on the shares following Q1 results. The firm noted that the revuforj…